Because RGC death is a hallmark of glaucoma, we examined RGC survival by immunostaining against RNA binding protein (RBPMS) 4 weeks after AAV-Cas13d treatment (Fig. 3F, Supplementary S4A). Here, RBPMS is linked to glaucoma.